Would you consider a trial of pembrolizumab in a patient with metastatic urothelial carcinoma progressing on atezolizumab?  

Given the apparently stronger results from KEYNOTE 052 (pembrolizumab) compared to IMvigor 211 (atezolizumab), would you consider pembrolizumab for patients progressing on atezolizumab?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Washington School of Medicine
Agree that we have no data to try another CPI afte...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution